Search results for "MAb"

Real-world experience with dupilumab in severe asthma: One-year data from an italian named patient program

2021

Raffaele Campisi,1 Claudia Crimi,1 Santi Nolasco,2 Bianca Beghè,3 Leonardo Antonicelli,4 Gabriella Guarnieri,5 Nicola Scichilone,6 Morena Porto,2 Luigi Macchia,7 Giulia Scioscia,8 Maria Pia Foschino Barbaro,8 Alberto Papi,9 Nunzio Crimi1,2 1Respiratory Medicine Unit, A.O.U. Policlinico “G. Rodolico -San Marco”, Catania, Italy; 2Department of Clinical and Experimental Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy; 3Respiratory Medicine Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 4Allergy Unit, Department of Internal Medicine, Ancona University Hospital, Ancona, Italy; 5Department of Car…

COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

2020

To the Editor Since the end of February 2020 Italy, first non- Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200,000 confirmed Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) infected subjects and resulted in more than 34000 deaths (data updated to June 19th, 20201).Patients with asthma are potentially more severely affected by by SARS-CoV-2 infection 2 and it is well established that respiratory viral infections are associated with severe adverse outcomes in patients with asthma, including increased risk of asthma exacerbation episodes 3. Nonetheless, according to the epidemiological studies publishe…

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

Towards Seamless IoT Device-Edge-Cloud Continuum:

2021

In this paper we revisit a taxonomy of client-side IoT software architectures that we presented a few years ago. We note that the emergence of inexpensive AI/ML hardware and new communication technologies are broadening the architectural options for IoT devices even further. These options can have a significant impact on the overall end-to-end architecture and topology of IoT systems, e.g., in determining how much computation can be performed on the edge of the network. We study the implications of the IoT device architecture choices in light of the new observations, as well as make some new predictions about future directions. Additionally, we make a case for isomorphic IoT systems in whic…

Optical quality of hyperopic and myopic phakic intraocular lenses

2013

Aims: To assess and compare the optical quality of the myopic and hyperopic implantable collamer lens (ICL) from its wavefront aberrations for different powers and pupil diameters. Settings and Design: Prospective study. Material and Methods: The wavefront aberrations of two myopic (−3 and −6 diopters (D)) and two hyperopic V4b ICLs (+3 and +6D) were measured in vitro . To assess and compare the optical quality of different powers of ICLs, we analyzed the root mean square (RMS) of total higher order aberrations (HOAs), trefoil, coma, tetrafoil, secondary astigmatism, and spherical aberration at 3- and 4.5-mm pupil. In addition, the point spread functions (PSFs) of each ICL evaluated were ca…

Análisis de la respuesta biomecánica, percepción del esfuerzo y confort en función del soporte plantar: termoconformable vs control durante un test d…

2020

En las últimas décadas se ha incrementado el número de corredores/as recreativos/as y competitivos/as en todo el mundo debido a los numerosos beneficios que conlleva la carrera a nivel físico, psicológico y social. Sin embargo, este incremento también ha supuesto en un aumento en la incidencia de lesiones en las extremidades inferiores. Entre las estrategias empleadas por los corredores/as para reducir la incidencia de lesiones durante la carrera está la utilización de soportes plantares. Además de los soportes prefabricados genéricos y los personalizados, surgen nuevos soportes como los termoconformables, los cuales pueden adaptarse a la ergonomía del pie calentándose por el propio usuario…

Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab.

2010

Impressive objective response to nab-paclitaxel plus trastuzumab as fifth line therapy in aelderly her2-positive breast cancer patient

2020

Agent targeting HER-2 pathway plus chemotherapy has represented a major progress in the management of patients with breast cancer. However the role of late-line treatment in heavily pretreated patients is largely unclear. In the last decade nab-paclitaxel has show significant activity and good toxicity profile in metastatic breast cancer. We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral ca…

Nuevas vías moleculares implicadas en los mecanismos de resistencia primaria y adquirida en cáncer de mama HER2 positivo

2018

El cáncer de mama es el tumor más frecuente en la mujer, representa aproximadamente el 28% de todas las neoplasias y es la principal causa de muerte por cáncer en las mujeres europeas. A pesar de los avances en el tratamiento y en el diagnóstico temprano, sigue siendo un importante problema de salud pública. El 20% de las pacientes diagnosticadas de cáncer de mama presentan una recaída. La enfermedad en estadios avanzados sigue siendo incurable con una supervivencia media de 2-3 años y una supervivencia global de 25% a los 5 años. El cáncer de mama es una enfermedad heterogénea que podemos clasificar en: luminal A, luminal B, HER2 amplificado o triple negativo en función de criterios anatom…

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of …

2006

Morbidity and mortality in patients with malignancies are increased by viral infections. These mostly are reactivations of asymptomatic latent infections. They primarily concern clinical entities associated with the reactivation of herpes viruses, such as varicella zoster virus (VZV) and cytomegalovirus (CMV). Respiratory tract infections caused by influenza, parainfluenza or respiratory syncytial virus (RSV) are less common. Since reactivation of latent infections has major clinical impact, antiviral prophylaxis is an attractive approach for patients expecting immunosuppression. The main risk factor for clinically relevant reactivation is profound disruption of cellular immune response. Du…